Deep Vein Thrombosis (DVT) — Clinical Documentation Guide (2026)

🔍 Definition

Deep vein thrombosis (DVT) is the formation of a blood clot (thrombus) within a deep vein, most commonly in the lower extremities — the femoral, popliteal, iliac, tibial, or peroneal veins — but also occurring in the upper extremities (brachial, radial, ulnar, axillary, subclavian, internal jugular veins) and less commonly in other sites (vena cava, renal vein, hepatic vein, cerebral sinuses). DVT is a major component of venous thromboembolism (VTE), the other being pulmonary embolism (PE), which occurs when a thrombus dislodges and migrates to the pulmonary vasculature.

The condition is classified as acute (new thrombus, typically within 4 weeks of onset) or chronic (post-thrombotic, residual thrombus >4 weeks, or evidence of chronic venous changes). This acute vs. chronic distinction drives ICD-10-CM code assignment and has direct implications for HCC risk adjustment and clinical management.

Globally, DVT affects an estimated 1–2 per 1,000 persons annually, according to CDC VTE data. In hospitalized patients, untreated DVT carries a risk of PE of approximately 40–50%, making accurate documentation and timely coding critical for both patient safety outcomes and appropriate reimbursement.

🗂️ Alternative Terminology

🩺 Signs & Symptoms

DVT is notoriously variable in presentation; up to 50% of cases are asymptomatic or minimally symptomatic. When present, classic findings include:

• Unilateral leg swelling (edema, increased limb circumference)
• Pain or tenderness along the course of the deep vein, often exacerbated by walking or dorsiflexion (Homans' sign — low specificity, rarely documented)
• Erythema or skin warmth over the affected limb
• Skin discoloration — cyanosis (phlegmasia cerulea dolens in massive DVT) or pallor/blanching (phlegmasia alba dolens)
• Dilated superficial veins (collateral vessel prominence)
• Pitting edema distal to obstruction

Upper extremity DVT may present with arm swelling, cyanosis, heaviness, or Paget-Schroetter syndrome (effort thrombosis in athletes/manual workers following strenuous use). Catheter-related upper extremity DVT is often asymptomatic and identified incidentally on imaging.

🧭 Differential Diagnosis

📋 Clinical Indicators for Coders/CDI

🦴 Anatomy & Pathophysiology

The deep venous system of the lower extremity consists of paired veins accompanying the major arteries: the anterior tibial, posterior tibial, and peroneal (fibular) veins (forming the calf/distal DVT vessels), which drain into the popliteal vein behind the knee. The popliteal vein ascends to become the femoral vein (in the adductor canal and femoral triangle), then joins the deep femoral vein to form the common femoral vein, which drains into the external iliac and common iliac veins, ultimately entering the inferior vena cava.

DVT pathogenesis is classically explained by Virchow's Triad — three interacting factors:

• Venous stasis (immobility, prolonged bed rest, long-haul travel, heart failure, obesity, paralysis)
• Endothelial injury (trauma, surgery, central venous catheters, prior DVT, vasculitis)
• Hypercoagulability (inherited thrombophilias — Factor V Leiden mutation [D68.51], prothrombin G20210A mutation [D68.52], antiphospholipid syndrome [D68.61]; acquired — malignancy, pregnancy, OCP use, inflammatory disease, heparin-induced thrombocytopenia)

Once a thrombus forms, it can propagate proximally (distal to proximal extension, increasing PE risk), embolize to the pulmonary arteries (PE — see separate CDG), or undergo fibrinolysis (spontaneous resolution) or organization (becoming chronic/fibrotic). Chronic thrombus damages venous valves, causing retrograde reflux, ambulatory venous hypertension, and ultimately post-thrombotic syndrome (PTS) — coded to I87.0xx.

The upper extremity deep venous system includes the radial, ulnar, brachial, axillary, subclavian, and internal jugular veins. Upper extremity DVT (UE-DVT) represents approximately 4–10% of all DVT cases and is increasingly catheter-related (central venous catheters, peripherally inserted central catheters [PICCs]).

💊 Medication Impact / Treatment

Anticoagulation is the cornerstone of DVT treatment. Drug selection affects coding and HCPCS billing:

• Initial/parenteral anticoagulation: Unfractionated heparin (UFH) IV infusion; Low-molecular-weight heparins (LMWH) — enoxaparin (Lovenox, J1650), dalteparin (Fragmin, J1645), fondaparinux (Arixtra, J1652)
• Oral anticoagulation (DOACs — Direct Oral Anticoagulants): Rivaroxaban (Xarelto), apixaban (Eliquis), dabigatran (Pradaxa), edoxaban (Savaysa) — reported via NDC on Medicare Part D claims
• Vitamin K antagonist: Warfarin (Coumadin) — oral, Part D NDC; requires INR monitoring
• Thrombolytics: Alteplase (tPA, J2997) — catheter-directed or systemic; reserved for massive/limb-threatening DVT (phlegmasia cerulea dolens), PE with hemodynamic instability
• Compression therapy: Graduated compression stockings — reduces post-thrombotic syndrome risk
• IVC filter placement: CPT 37193 — reserved for patients with anticoagulation contraindication or recurrent PE
• Mechanical thrombectomy: CPT 37187/37188 — catheter-directed mechanical thrombectomy for extensive proximal DVT

Documentation of anticoagulation therapy triggers the additional code Z79.01 (long-term use of anticoagulants) when the anticoagulant is prescribed for ongoing use beyond the acute episode. This code is reportable for both inpatient and outpatient encounters per FY2026 ICD-10-CM Official Guidelines, Section I.C.21.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides